Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10878380PMC
http://dx.doi.org/10.1164/rccm.202312-2248EDDOI Listing

Publication Analysis

Top Keywords

bronchodilator responsiveness
4
responsiveness asthma
4
asthma chronic
4
chronic obstructive
4
obstructive pulmonary
4
pulmonary disease
4
disease time
4
time chasing
4
chasing shadows
4
bronchodilator
1

Similar Publications

Introduction: A main feature of CDH is lung hypoplasia and the related presentation of pulmonary hypertension and cardiac dysfunction. Multiple factors influence pulmonary status after CDH: degree of hypoplasia, ventilator-induced injury, altered growth and development of pulmonary structures, reduced diaphragm function and chest wall abnormalities. The evolution of pulmonary sequela in this population is still unclear.

View Article and Find Full Text PDF

: The aim of this study was to investigate the effect of substrate - polycaprolactone (PCL)-based porous membrane modified with rosmarinic acid (RA), (PCL-RA) and to determine the optimal values of low field laser irradiation (LLLT) as stimulators of biological response of RAW 264.7 macrophages. : The porous polymer membrane was obtained by the phase inversion method, the addition of rosmarinic acid was 1%wt.

View Article and Find Full Text PDF

Objective: This study evaluated the safety and efficacy of isoproterenol administration as an adjunct for achievement of target heart rate (HR) during dobutamine stress echocardiography (DSE).

Background: In DSE, optimal accuracy is achieved when a target HR of 85% of maximal predicted heart rate (MPHR) is attained. Although rarely studied, intravenous isoproterenol has been used as an adjunct therapy to dobutamine and atropine to increase chronotropic response during pharmacologic stress testing.

View Article and Find Full Text PDF

Background: In patients with asthma, bronchoconstriction and airway inflammation both contribute to airway narrowing and airflow limitations, which lead to symptoms and exacerbations. Short-acting beta 2-agonist (SABA)-only rescue therapy addresses only bronchoconstriction and is associated with increased morbidity and mortality. Current asthma management guidelines recommend concomitant treatment of symptoms and inflammation with a fast-acting bronchodilator and inhaled corticosteroid (ICS) as rescue therapy for patients 12 years of age.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!